This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD276. Enoblituzumab is a humanized monoclonal antibody that can be potentially used in the treatment of Solid tumors.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human CD276 Recombinant Antibody (Enoblituzumab)Recombinant monoclonal antibody to CD276. Enoblituzumab is a humanized monoclonal antibody that can be potentially used in the treatment of Solid tumors.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-117CL | Anti-Human CD276 Recombinant Antibody (MGA271) | ADCC, FuncS | Antibody |
TAB-424CQ | Anti-Human CD276 Recombinant Antibody (Enoblituzumab) | ELISA, IHC, FC, IP, IF, FuncS | IgG1, κ |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# AFC-TAB-424CQ, RRID: AB_3111284)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.